Background: Vanillosmopsis arborea Baker has recognized economic value owing to the high content of (-)-α-bisabolol (BISA) in the essential oil of its stem (EOVA). The antinociceptive effect of EVOA has already been demonstrated, and β-cyclodextrin (βCD) is known to improve the analgesic effect of various substances.
Purpose: Thus, we aimed to evaluate the orofacial antinociceptive effect of a complex containing EOVA-βCD in rodents.
Methods: EOVA was obtained by simple hydrodistillation, and the essential oil was complexed with βCD. The animals (n = 6/group) were treated orally with EOVA-βCD (10 or 50 mg/kg), or vehicle (control), and subjected to cutaneous orofacial nociception (formalin, capsaicin, acidic saline or glutamate), corneal (hypertonic saline) or temporomandibular (formalin) tests. The expression of FOS protein was analyzed in the spinal cord. Molecular docking was performed using the 5-HT and M receptors and BISA.
Results: The oral administration of EOVA-βCD reduced nociceptive behaviour. Moreover, EOVA-βCD decreased FOS expression. The molecular docking study indicates that BISA interacts with 5-HT3 and M2 receptors, indicating the potential mechanism of action of the tested compound.
Conclusions: Our results indicate that EOVA-βCD possesses orofacial antinociceptive effect, indicating that this complex can be used in analgesic drug development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2018.09.173 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal Treatment with Cannabinoid 2 Receptor Agonist HU-308 Ameliorates Cold Sensitivity in Mice with Traumatic Trigeminal Neuropathic Pain.
Cells
November 2024
Department of Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
Post-traumatic trigeminal neuropathy (PTTN) is a sensory abnormality caused by injury to the trigeminal nerve during orofacial surgery. However, existing analgesics are ineffective against PTTN. Abnormal microglial activation in the caudal part of the spinal trigeminal nucleus caudal part (Sp5C), where the central trigeminal nerve terminals reside, plays an important role in PTTN pathogenesis.
View Article and Find Full Text PDFEnhancing orofacial pain relief: α-phellandrene complexed with hydroxypropyl-β-cyclodextrin mitigates orofacial nociception in rodents.
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Department of Physiology, Federal University of Sergipe (UFS), São Cristóvão, SE, Brazil.
Orofacial pain affects 10-15% of adults and can severely impact quality of life. Despite ongoing treatment challenges, monoterpene alpha-phellandrene (PHE) shows potential therapeutic benefits. This study aimed to develop and evaluate an inclusion complex of PHE with hydroxypropyl-beta-cyclodextrin (PHE-HPβCD) for treating orofacial pain.
View Article and Find Full Text PDFNovel apocynin regulates TRPV1 activity in the trigeminal system and controls pain in a temporomandibular joint neurogenic model.
Eur J Pharmacol
December 2024
Faculdade São Leopoldo Mandic, Campinas, SP, Brazil. Electronic address:
Objective: Herein, we investigate the potential analgesic effect of a newly synthesized chalcone-derived apocynin in a neurogenic pain model.
Methods: Molecular docking was used to foretell the apocynin binding features and dynamics with the TRPV1 channel, and the activity was tested in vitro, using transfected HEK 293T cells with the rat TRPV1 receptor. The analgesic effect of apocynin was investigated using a capsaicin-induced pain model.
PAR on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451.
Biomaterials
March 2025
New York University Dentistry Translational Research Center, New York University Dentistry, New York, NY, 10010, USA; Pain Research Center, New York University, New York, NY, 10010, USA; Department of Neuroscience and Physiology, New York University Grossman School of Medicine, New York, NY, 10016, USA. Electronic address:
Article Synopsis
- Oral cancer causes significant pain linked to the activation of protease-activated receptor 2 (PAR) in cancer cells and neurons, contributing to nociception (pain sensation).
- Researchers found that inhibiting PAR using nanoparticles to deliver the drug AZ3451 is more effective in reversing pain compared to the drug alone, especially in mouse models of oral cancer pain.
- The study also shows that both the overexpression of the F2RL1 gene in cancer cells and neurons plays a role in pain, and targeting PAR could improve pain management and oral function for patients.
Blockade of Piezo2 Pathway Attenuates Inflammatory and Neuropathic Pain in the Orofacial Area.
Pain Res Manag
October 2024
Department of Oral Physiology School of Dentistry Kyungpook National University, Daegu, Republic of Korea.
Although previous studies suggest that Piezo2 regulates chronic pain in the orofacial area, few studies have reported the direct evidence of Piezo2's involvement in inflammatory and neuropathic pain in the orofacial region. In this study, we used male Sprague Dawley rats to investigate the role of the Piezo2 pathway in the development of inflammatory and neuropathic pain. The present study used interleukin (IL)-1-induced pronociception as an inflammatory pain model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!